The duo plan to establish a global center of excellence in theranostics, taking advantage of Siemens’ state-of-the-art technology and software to advance the use of radiopharmaceuticals in cancer care.
Black patients are already less likely to receive LVADs or transplants compared to whites, and these inaccurate readings can further widen the disparities.